Zynex Inc Stock Price, News & Analysis

Zynex, Inc. (NASDAQ: ZYXI), a medical technology company, announced the change of its independent registered accounting firm from Plante & Moran to Marcum LLP, effective June 13, 2022. This decision followed a thorough evaluation process and received approval from the Board of Directors and Audit Committee. CEO Thomas Sandgaard expressed gratitude to Plante & Moran for their service over the past five years, indicating no disagreements or reportable events during that period. Zynex specializes in non-invasive medical devices for pain management and rehabilitation.

Zynex, Inc. (NASDAQ: ZYXI) announced a $10 million share buyback program effective from June 10, 2022, aimed at enhancing shareholder value and reflecting board confidence in the company's growth strategy. This program follows the completion of a previous buyback in less than 50 days. The purchase will be financed through existing cash balances and is not expected to materially impact capital levels. The board believes the current market value does not accurately represent the company's true value, making this buyback an attractive opportunity for capital deployment.

Zynex, a leading medical technology company, will participate in two key investor conferences in May 2022. The management will present virtually at the H.C. Wainwright Annual Global Investment Conference on May 24, 2022, at 7 AM ET. Additionally, Zynex will present at the UBS Global Healthcare Conference on May 25, 2022, at 12:15 PM ET. Investors can access webcasts of both events through the company's investor relations website. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring.

Zynex reported a strong first quarter for 2022, with revenue increasing 29% year-over-year to $31.1 million. Net income soared 296% to $1.4 million, resulting in a diluted EPS of $0.03. Adjusted EBITDA surged 897% to $3.1 million. The company announced a $10 million share buyback program signaling confidence in its long-term strategy. For 2022, Zynex estimates full-year revenue between $150-$170 million and adjusted EBITDA of $25-$35 million.

Zynex, a medical technology company, will release its first quarter 2022 financial results on April 28, 2022. The conference call and webcast will be held at 4:15 p.m. ET to discuss the results and provide a corporate update. Zynex specializes in non-invasive medical devices for pain management and patient monitoring. For further details on the event, interested parties can register through a provided link.

Zynex, Inc. (NASDAQ: ZYXI) announced a $10 million share buyback program, effective from April 12, 2022 to April 11, 2023, aimed at enhancing shareholder value. CEO Thomas Sandgaard expressed confidence in the company’s growth potential, stating that the current market value does not reflect its true value. The buybacks will occur in the open market and will be funded through existing cash balances, without a significant impact on capital levels. As of April 8, 2022, the company had approximately 39.8 million shares outstanding.

Zynex, Inc. (NASDAQ: ZYXI) reported preliminary Q1 2022 revenue ranging from $30.5 to $31.5 million, reflecting a 26% year-over-year increase, and adjusted EBITDA of $3.0 to $4.0 million, an approximately 900% rise. The company maintains its full-year 2022 guidance of $150 to $170 million in revenue and adjusted EBITDA between $25 and $35 million. The pain management division achieved a 3% growth in orders year-over-year despite a reduced sales force. New product additions, including knee braces, boosted orders significantly, with the highest orders recorded in March 2022.